Given the widespread use of thiopurines, and magnitude of individuals infected with hepatitis C, while considering that roughly one third of the world population has ITPA polymorphism, it seems plausible that development of these therapies will be met with considerable need. This evidence concerns the gene ITPA and hepatitis C virus infection.